Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Withdrawn 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Other 4Myeloid 1Lymphoid 1

Conditions

Mucositis 4Hematologic Neoplasms 3Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Graft vs Host Disease 1

Interventions

Radiotherapy 9Cisplatin 8Fibroblast Growth Factor 7 6Low-Level Light Therapy 5angiotensin I (1-7) 4Radiation 4Injections 4Propolis 3Morphine 3Methotrexate 3Leucovorin 3Drug Therapy 3Cryotherapy 3glucarpidase 2aluminum hydroxide, magnesium hydroxide, drug combination 2Xylitol 2Water 2Radiotherapy, Intensity-Modulated 2RRx-001 2Probiotics 2Pentoxifylline 2Mouthwashes 2Melphalan 2Lidocaine 2Ketamine 2Interleukin 1 Receptor Antagonist Protein 2Honey 2Glutamine 2Gabapentin 2Fluorouracil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Mucositis × angiotensin I (1-7) × Other × Clear all
NCT01300611 2020-12-08

USBTXA127CBT

Tarix Pharmaceuticals

Phase 1 Terminated
20 enrolled
LymphoidMyeloidOtherOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Mucositis, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT01554254 2016-08-31

Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Hematologic Neoplasms, Mucositis

NCT01882374 2016-08-31

Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Hematologic Neoplasms, Mucositis

NCT01882387 2016-08-31

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡